메뉴 건너뛰기
American Family Physician
Volumn 82, Issue 12, 2010, Pages 1546-1547
Bivalent HPV recombinant vaccine (Cervarix) for the prevention of cervical cancer
Author keywords

[No Author keywords available]
Indexed keywords

WART VIRUS VACCINE;
EID: 79956342115     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (1)
References (7)
  • 1
    • 79956361698 scopus 로고    scopus 로고
    • Cervarix (bivalent human papillomavirus [types 16 and 18] recombinant vaccine) [prescribing information]. Research Triangle Park, N.C.: GlaxoSmithKline Biological, Accessed February 9
    • Cervarix (bivalent human papillomavirus [types 16 and 18] recombinant vaccine) [prescribing information]. Research Triangle Park, N.C.: GlaxoSmithKline Biological. http://us.gsk.com/products/assets/us_cervarix.pdf. Accessed February 9, 2010.
    • (2010)
  • 2
    • 84878938627 scopus 로고    scopus 로고
    • FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) [published correction appears in, ]
    • FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 2010;59(36):1184].
    • (2010) MMWR Morb Mortal Wkly Rep , vol.59 , Issue.36 , pp. 1184
  • 3
    • 77953080981 scopus 로고    scopus 로고
    • Accessed November 15, 2010
    • MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_cid=mm5920a4_e. Accessed November 15, 2010.
    • (2010) MMWR Morb Mortal Wkly Rep , vol.59 , Issue.20 , pp. 626-629
  • 4
    • 71649087760 scopus 로고    scopus 로고
    • Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years
    • GlaxoSmithKline Vaccine HPV-007 Study Group
    • GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374(9706):1975-1985.
    • (2009) Lancet , vol.374 , Issue.9706 , pp. 1975-1985
    • Romanowski, B.1    de Borba, P.C.2
  • 6
    • 71649091113 scopus 로고    scopus 로고
    • Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
    • HPV-010 Study Group
    • Einstein MH, Baron M, Levin MJ, et al.; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705-719.
    • (2009) Hum Vaccin , vol.5 , Issue.10 , pp. 705-719
    • Einstein, M.H.1    Baron, M.2    Levin, M.J.3
  • 7
    • 80052550379 scopus 로고    scopus 로고
    • Montvale, N.J.: Medical Economics Data
    • Red Book. Montvale, N.J.: Medical Economics Data; 2010.
    • (2010) Red Book

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.